Responses... Hi Chazzle, "From what I can te
Post# of 148096
(Total Views: 527)
Posted On: 07/31/2023 11:10:33 PM
Responses...
Hi Chazzle,
"From what I can tell, no mention of Leronlimab. Same at MDAndersen."
-The database you linked to only lists human studies. The Leron/Keytruda/MD Anderson study utilizes a Xenograft Model (mice; thus it wouldn't show up in that database):
Xenograft models are based on the implantation of human tumor cells into immunocompromised mice to avoid graft versus host reaction of the mouse against the human tumor tissue.
More here (including MD Anderson reference): https://www.biospace.com/article/releases/cyt...kade-icb-/
Hi Craig,
"but if CYDY had the money, could they be doing a NASH trial right now?"
-Guessing CYDY doesn't receive the bulk of partnership money until the hold is released and partnership announced, hence no NASH trial (yet). When CYDY gets the cash (from partner or Amawrecks), things will start to positively snowball on all fronts. Note Antonio's mention of NASH trial protocol submission happening subsequent to HIV hold submission in September.
"Still wondering what happened to all of the oncology talk from months ago as that was to be CYDY's main focus, but as we know, was never mentioned in the latest CC."
-NDAs, or non-disclosure agreements, are legally enforceable contracts that create a confidential relationship between a person who has sensitive information and a person who will gain access to that information. A confidential relationship means one or both parties has a duty not to share that information.
Hi USS Johnston,
"With so little profit to be gained, it seems the only intent of this shorting is to send us into BK."
-Once the shorts see that bk is officially off the table (via Amawrecks settlement and/or partnership $), I suspect things will change for the better in terms of the excessive shorting. Also, uplisting to the more highly regulated Nasdaq (which will likely happen after a few pieces of good CYDY news) should help diminish whatever shenanigans may currently be at play.
FYI - oldie but goodie (I'll refrain from sharing my views on Pestell, but the content here is relevant and interesting re: oncology/ccr5): https://www.youtube.com/watch?v=pUWhc_jXxCg
Hi Chazzle,
"From what I can tell, no mention of Leronlimab. Same at MDAndersen."
-The database you linked to only lists human studies. The Leron/Keytruda/MD Anderson study utilizes a Xenograft Model (mice; thus it wouldn't show up in that database):
Xenograft models are based on the implantation of human tumor cells into immunocompromised mice to avoid graft versus host reaction of the mouse against the human tumor tissue.
More here (including MD Anderson reference): https://www.biospace.com/article/releases/cyt...kade-icb-/
Hi Craig,
"but if CYDY had the money, could they be doing a NASH trial right now?"
-Guessing CYDY doesn't receive the bulk of partnership money until the hold is released and partnership announced, hence no NASH trial (yet). When CYDY gets the cash (from partner or Amawrecks), things will start to positively snowball on all fronts. Note Antonio's mention of NASH trial protocol submission happening subsequent to HIV hold submission in September.
"Still wondering what happened to all of the oncology talk from months ago as that was to be CYDY's main focus, but as we know, was never mentioned in the latest CC."
-NDAs, or non-disclosure agreements, are legally enforceable contracts that create a confidential relationship between a person who has sensitive information and a person who will gain access to that information. A confidential relationship means one or both parties has a duty not to share that information.
Hi USS Johnston,
"With so little profit to be gained, it seems the only intent of this shorting is to send us into BK."
-Once the shorts see that bk is officially off the table (via Amawrecks settlement and/or partnership $), I suspect things will change for the better in terms of the excessive shorting. Also, uplisting to the more highly regulated Nasdaq (which will likely happen after a few pieces of good CYDY news) should help diminish whatever shenanigans may currently be at play.
FYI - oldie but goodie (I'll refrain from sharing my views on Pestell, but the content here is relevant and interesting re: oncology/ccr5): https://www.youtube.com/watch?v=pUWhc_jXxCg
(19)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼